Rita Barcia

Company: SIRPant Immunotherapeutics

Job title: Vice President, Process Development & Operations

Seminars:

A Novel Approach to Cancer-Agnostic Treatment of Tumors With Non-Genetically Modified Macrophages 2:00 pm

SIRpant uses a non-genetic approach to reprogramming macrophages that removes SIRPɑ and simultaneously reprograms them to promote an anti-cancer response whilst reducing manufacturing time  Our macrophages act by directly attacking cancerous cells, stimulating cancer neoantigen-specific cytotoxic T cells and antibodies, reducing immunosuppressive elements, and perpetuating a pro-inflammatory TME that favors cancer elimination  Overcoming manufacturing challenges…Read more

day: Day One Track A PM